Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

天安卓健有限公司
TIAN AN MEDICARE LIMITED
(Incorporated in Bermuda with limited liability)
(Stock Code: 383)

PROFIT WARNING

This announcement is made by Tian An Medicare Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 and information currently available, subject to any impairment adjustment(s), fair value change and/or provision adjustment(s) on properties or other adjustment(s), the Group is expected to record a profit attributable to Shareholders in the estimated range of approximately HK$7.0 million to HK$17.0 million for the six months ended 30 June 2025 as compared with the profit attributable to the Shareholders of approximately HK$21.7 million for the six months ended 30 June 2024 ("**HY2024**"). This was mainly due to (i) the decrease in revenue from operations of the Healthcare Division; (ii) the increase in non-cash loss on fair value of investment properties but were partially off-set by (iii) the decrease in employee benefits expense; (iv) the unrealised net foreign exchange gain versus the unrealised net foreign exchange loss in HY2024; and (v) the decrease in income tax expense.

This profit warning announcement is only based on the preliminary review on the relevant unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 and information currently available, which have not been confirmed or reviewed by the auditor nor reviewed by the audit committee of the Company, and therefore is subject to adjustments where necessary. Accordingly, the actual results of the Group for the six months ended 30 June 2025 may be different from what is disclosed in this announcement. The Company is in the process of finalizing the interim results for the six months ended 30 June 2025. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2025, which is expected to be released in August 2025.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

On behalf of the Board
Tian An Medicare Limited
Kong Muk Yin
Executive Director

Hong Kong, 28 July 2025

As at the date of this announcement, the Board comprises Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying being Executive Directors; Mr. Lee Seng Hui (Chairman), Mr. Mark Wong Tai Chun, Mr. Gao Zhaoyuan and Ms. Zhang Yuanyuan being Non-Executive Directors; and Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert, Ms. Yang Lai Sum, Lisa and Mr. Cao Dan being Independent Non-Executive Directors.